Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBI-100 in glaucoma and ocular hypertension
NCT06144918Phase 2Completed
- Sponsor
- Skye Bioscience
- Start
- Nov 2023
- Primary completion
- Feb 2024
- Modality
- Lipid-based Nanoparticles, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SBI-100 in primary open-angle glaucoma (POAG) and ocular hypertension (3 arms), sponsored by Skye Bioscience. Primary endpoints: Change From Baseline in Intraocular Pressure at 14 days and Treatment Emergent Adverse Events at 16 days. Started Nov 2023; status: completed.
02
Drugs
SBI-100
03
Conditions
primary open-angle glaucoma (POAG)ocular hypertension
Beyond the preview
Go deeper on NCT06144918.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06144918.